Article
Oncology
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. B. Lahoud, Heather J. J. Landau, David J. J. Chung, Gunjan L. L. Shah, Michael Scordo, Sergio A. A. Giralt, Alexander Lesokhin, Saad Z. Z. Usmani, Ola Landgren, Neha Korde
Summary: This retrospective study compared the efficacy and safety of VRd and KRd as induction regimens. The results showed that KRd was associated with improved progression-free survival (PFS) and event-free survival (EFS) compared to VRd, with a more significant improvement observed in high-risk patients.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Elisabetta Antonioli, Sofia Pilerci, Irene Attucci, Gabriele Buda, Alessandro Gozzetti, Veronica Candi, Federico Simonetti, Maria Livia Del Giudice, Sara Ciofini, Michela Staderini, Sara Grammatico, Alessandra Buzzichelli, Maria Messeri, Monica Bocchia, Sara Galimberti, Alessandro. M. M. Vannucchi
Summary: This multicenter prospective observational study evaluated the efficacy of KRd combination therapy for multiple myeloma. The results showed an overall response rate of 95% and a median progression-free survival of 36 months. Patients who underwent autologous stem cell transplantation and achieved at least very good partial remission had longer progression-free survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Joshua Richter, Peggy L. Lin, Viviana Garcia-Horton, Patricia Guyot, Erin Singh, Zheng-Yi Zhou, Mark Sievert, Riley Taiji
Summary: In this study, the efficacy and safety of Isa-Kd was compared with Dara-Rd for early relapse in patients with RRMM. Isa-Kd showed better PFS, OS, and fewer TEAEs compared to Dara-Rd. These results suggest that Isa-Kd could be an effective treatment option for early relapse in non-lenalidomide refractory patients.
Article
Oncology
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro
Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.
Article
Oncology
Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Mueller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, Nicola Giesen
Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.
Article
Hematology
Peter A. Forsberg, Adriana C. Rossi, Angelique Boyer, Roger N. Pearse, Karen A. Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, Scott Ely, Leora Boussi, John N. Allan, Morton Coleman, Ruben Niesvizky, Tomer M. Mark
Summary: The study evaluated a new treatment regimen for multiple myeloma called Car-BiRd and found that it can achieve similar outcomes with reduced toxicities compared to standard treatment regimens. The results showed a high overall response rate in newly diagnosed MM patients and suggest that the sequential Car-BiRd regimen is an effective and safe approach for upfront treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Mueller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel
Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Hematology
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, Hideo Yagi, Yuzuru Kanakura, Itaru Matsumura, Masayuki Hino, Shosaku Nomura, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda
Summary: This retrospective analysis evaluated the real-world survival benefits and safety profiles of KRd and Kd therapies. The results showed that the reduction of carfilzomib dose and refractoriness to prior treatments were associated with lower survival rates. Adverse events were common in both therapies.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Medicine, General & Internal
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Spicka, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Mace, Thomas Martin
Summary: The study showed that the addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Anna Mele, Eleonora Prete, Clara De Risi, Stefania Citiso, Giuseppina Greco, Antonietta Pia Falcone, Grazia Sanpaolo, Giuseppe Mele, Angela Giannotta, Carolina Vergine, Giovanni Reddiconto, Giulia Palazzo, Sabrina Sabatelli, Candida Germano, Rosanna Miccolis, Paola Curci, Gaetano Palumbo, Massimo Offidani, Rita Rizzi, Nicola Cascavilla, Domenico Pastore, Nicola Di Renzo, Patrizio Mazza, Giuseppe Tarantini, Attilio Guarini, Silvana Capalbo, Giorgina Specchia, Antonino Greco, Rosa De Francesco, Silvia Sibilla, Lorenzo Tonialini, Maria Rosaria Morciano, Vincenzo Pavone
Summary: This retrospective study evaluated 130 consecutive RRMM patients treated with KRd, showing that KRd is effective and well-tolerated, serving as a bridge regimen to ASCT. Patients achieving VGPR, those naive to lenalidomide, and patients relapsing after ASCT demonstrated longer PFS.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Anna Astarita, Giulia Mingrone, Lorenzo Airale, Marco Cesareo, Anna Colomba, Cinzia Catarinella, Dario Leone, Francesca Gay, Sara Bringhen, Franco Veglio, Alberto Milan, Fabrizio Vallelonga
Summary: The purpose of this study was to compare the incidence and time of onset of cardiovascular complications induced by Carfilzomib-dexamethasone and Carfilzomib-lenalidomide-dexamethasone in patients with multiple myeloma. The results showed that the Carfilzomib-dexamethasone group had a higher incidence and earlier onset of cardiovascular events, while the Carfilzomib-lenalidomide-dexamethasone group was more likely to develop signs of cardiac and vascular damage.
Article
Hematology
Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cecile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hebraud, Jill Corre, Michel Attal
Summary: The study shows that using carfilzomib, lenalidomide, and dexamethasone in combination with transplant treatment for eligible patients with newly diagnosed multiple myeloma can produce rapid and deep responses, with an acceptable safety profile. Close monitoring of cardiovascular adverse events is necessary.
Article
Oncology
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, Candis Morrison, Joseph Roswarski, Neha Korde, Michael Emanuel, Ani Petrosyan, Manisha Bhutani, Katherine R. Calvo, Alina Dulau-Florea, Mary Kwok, Min-Jung Lee, Sunmin Lee, Liza Lindenberg, Sham Mailankody, Elisabet Manasanch, Irina Maric, Esther Mena, Nisha Patel, Nishant Tageja, Jane B. Trepel, Baris Turkbey, Hao-Wei Wang, Weixin Wang, Constance Yuan, Yong Zhang, Raul Braylan, Peter Choyke, Maryalice Stetler-Stevenson, Seth M. Steinberg, William D. Figg, Mark Roschewski, Ola Landgren
Summary: Treatment with novel triplet regimens such as KRd and lenalidomide maintenance therapy for high-risk smoldering myeloma may significantly delay the progression to symptomatic multiple myeloma, altering the natural history of the disease. Further randomized clinical trials are needed to confirm the favorable benefit-to-risk profile observed in this phase 2 trial.
Article
Oncology
Meletios A. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, David Yao, Prianka Das, Jesus San-Miguel
Summary: In the phase II ELOQUENT-3 trial, the combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd) showed significant improvement in progression-free survival (PFS) compared to Pomalidomide and Dexamethasone (Pd) in relapsed/refractory multiple myeloma patients previously treated with Lenalidomide and a proteasome inhibitor. The final overall survival (OS) results revealed that EPd had a statistically significant improvement in OS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Jens Hillengass, Tom Martin, Noemi Puig, Bruno Paiva, Saad Usmani, Shaji Kumar, Jesus San-Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Vladimir Maisnar, Ludek Pour, Ivan Spicka, Tomas Jelinek, Jiri Minarik, Alexandra Jungova, Martin Stork, Jan Straub, Jakub Radocha, Tomas Pika, Lenka Pospisilova, Sandhya Nair, Peter Kunovszki, Roman Hajek
Summary: A study analyzed data from the Czech Registry of Monoclonal Gammopathies and found that among 83 triple-class exposed relapsed/refractory multiple myeloma patients, the median overall survival was 14.2 months, progression-free survival was 6.2 months, and time to next treatment was 7.2 months. These results indicate a high disease burden in this patient population, consistent with previous studies.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Michael A. Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Katja C. Weisel, Robert M. Rifkin, Saad Z. Usmani, Roman Hajek, Gordon Cook, Rafat Abonour, Mira Armour, Kathryn E. Morgan, Su-Peng Yeh, Caitlin L. Costello, Jesus G. Berdeja, Faith E. Davies, Jeffrey A. Zonder, Hans C. Lee, Jim Omel, Andrew Spencer, Evangelos Terpos, Vania T. M. Hungria, Noemi Puig, Chengcheng Fu, Renda H. Ferrari, Kaili Ren, Dawn Marie Stull, Ajai Chari
Summary: We analyzed the vaccination rates of patients with multiple myeloma in the INSIGHT MM study and found that influenza and pneumococcal vaccination had an impact on overall survival. Additionally, vaccinated patients had fewer deaths due to infections compared to non-vaccinated patients. Recording vaccination status is important in prospective clinical trials as it may affect survival.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Summary: Based on the analysis of POLLUX, daratumumab in combination with lenalidomide and dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. The final analysis also showed that this combination therapy improved overall survival in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Meletios A. Dimopoulos, Jesus San-Miguel
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Medicine, Research & Experimental
Piotr Celichowski, Marcello Turi, Sandra Charvatova, Dhwani Radhakrishnan, Neda Feizi, Zuzana Chyra, Michal Simicek, Tomas Jelinek, Juli Rodriguez Bago, Roman Hajek, Matous Hrdinka
Summary: Cancer immunotherapies using genetically engineered T cells, particularly CAR T cell therapy, have shown promising results in hematological malignancies. To improve outcomes and reduce side effects, scientists are collaborating to develop next-generation CAR T cells using advanced tools and technologies from molecular cell biology and synthetic biology.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Oncology
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Michel Delforge, Gordon Cook, Francesca Gay, Niels W. C. J. van de Donk, Ioannis Ntanasis-Stathopoulos, Annette Juul Vangsted, Christoph Driessen, Fredrik Schjesvold, Claudio Cerchione, Sonja Zweegman, Roman Hajek, Philippe Moreau, Hermann Einsele, Jesus San-Miguel, Mario Boccadoro, Meletios A. A. Dimopoulos, Pieter Sonneveld, Heinz Ludwig
Summary: In the post-pandemic COVID-19 period, patients with multiple myeloma (MM) are at increased risk for severe COVID-19 outcomes. The European Myeloma Network recommends vaccination with variant-specific booster vaccines every 6-12 months to overcome the emergence of novel strains. Evaluation of immune response after vaccination can identify vulnerable patients who may need additional boosters and preventive measures. Certain antiviral drugs are effective against specific Omicron subvariants and should be administered in MM patients with positive COVID-19 tests or symptoms.
Article
Biochemistry & Molecular Biology
Marta Larrayoz, Maria J. Garcia-Barchino, Jon Celay, Amaia Etxebeste, Maddalen Jimenez, Cristina Perez, Raquel Ordonez, Cesar Cobaleda, Cirino Botta, Vicente Fresquet, Sergio Roa, Ibai Goicoechea, Catarina Maia, Miren Lasaga, Marta Chesi, P. Leif Bergsagel, Maria J. Larrayoz, Maria J. Calasanz, Elena Campos-Sanchez, Jorge Martinez-Cano, Carlos Panizo, Paula Rodriguez-Otero, Silvestre Vicent, Giovanna Roncador, Patricia Gonzalez, Satoru Takahashi, Samuel G. Katz, Loren D. Walensky, Shannon M. Ruppert, Elisabeth A. Lasater, Maria Amann, Teresa Lozano, Diana Llopiz, Pablo Sarobe, Juan J. Lasarte, Nuria Planell, David Gomez-Cabrero, Olga Kudryashova, Anna Kurilovich, Maria V. Revuelta, Leandro Cerchietti, Xabier Agirre, Jesus San Miguel, Bruno Paiva, Felipe Prosper, Jose A. Martinez-Climent
Summary: The lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) has hindered therapeutic discoveries. To overcome this limitation, researchers used genetically engineered mice to develop bone marrow tumors that mimic MM pathogenesis. Integrative analyses of mice and patients revealed a common genetic pathway that accelerates disease progression and immune evasion mechanisms that remodel the bone marrow microenvironment differently.
Article
Medicine, General & Internal
Jesus San-Miguel, Binod Dhakal, Kwee Yong, Andrew Spencer, Sebastien Anguille, Maria-Victoria Mateos, Carlos Fernandez de Larrea, Joaquin Martinez-Lopez, Philippe Moreau, Cyrille Touzeau, Xavier Leleu, Irit Avivi, Michele Cavo, Tadao Ishida, Seok Jin Kim, Wilfried Roeloffzen, Niels W. C. J. van de Donk, Dominik Dytfeld, Surbhi Sidana, Luciano J. Costa, Albert Oriol, Rakesh Popat, Abdullah M. Khan, Yael C. Cohen, P. Joy Ho, James Griffin, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Jordan M. Schecter, Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, T. Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele
Summary: In patients with lenalidomide-refractory multiple myeloma, Ciltacabtagene autoleucel (CAR-T cell therapy) showed a lower risk of disease progression or death compared to standard care, highlighting its effectiveness in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Hematology
Katja Weisel, Meletios A. Dimopoulos, Jesus San-Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord-Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michele Cavo
Summary: Triplet regimens with immunomodulatory drugs and proteasome inhibitors have improved outcomes for patients with relapsed/refractory multiple myeloma. In the ELOQUENT-3 trial, the addition of elotuzumab to pomalidomide and dexamethasone did not impact the health-related quality of life (HRQoL) of patients. HRQoL remained stable and there were no significant differences between the treatment arms.
Meeting Abstract
Oncology
Meletios Dimopoulos, Wee Joo Chng, Shinsuke Iida, Maria-Victoria Mateos, Gareth Morgan, Sagar Lonial, Ivan Spicka, Hang Quach, Albert Oriol, Roman Hajek, Mamta Garg, Nicola Giuliani, Meral Beksac, Eirini Katodritou, Sara Bringhen, Cong Li, Xiaoquan Zhang, Richard Labotka, Vincent Rajkumar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Tomas Jelinek, Ludmila Muronova, David Zihala, Tereza Sevcikova, Tereza Popkova, Hana Plonkova, Ondrej Venglar, Ludek Pour, Martin Stork, Lucie Rihova, Renata Bezdekova, Jiri Minarik, Martin Novak, Alexandra Jungova, David Chena, Jan Straub, Martin Spacek, Vladimira Rezacova, Ondrej Soucek, Vladimir Maisnar, Jakub Radocha, Roman Hajek
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Maria-Victoria Mateos, Monika Szarejko, Jelena Bila, Fredrik Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hajek, Hanna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Paul Richardson, Ludek Pour
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Enrique Ocio, Yvonne Efebera, Roman Hajek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, Maria-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul Richardson, Stefan Norin, Jakob Obermuller, Nicolaas Bakker, Ludek Pour
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)